Usability of Mixed Reality for Naloxone Training: Iterative Development and Field Testing of ReviveXR
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Setting
2.2. Study Design
2.3. ReviveXR Prototype Development
2.4. Modifications of the Prototype
2.5. ReviveXR Field Testing
2.6. Statistical Methods
3. Results
3.1. Effects on Knowledge
3.2. Effects on Confidence
3.3. Effects on Uncertainty
3.4. Effects on Intent
3.5. Learning Self-Efficacy
3.6. Qualitative Feedback
4. Discussion
4.1. Implications for Future Practice and Research
4.2. Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
AI | Artificial intelligence |
AHA | American Heart Association |
CDC | Centers for Disease Control and Prevention |
COVID-19 | Coronavirus disease 2019 |
CPR | Cardiopulmonary resuscitation |
FDA | Food and Drug Administration |
IRB | Institutional Review Board |
IT | Information technology |
JEC | Congress Joint Economic Committee |
L-SES | Learning Self-Efficacy Scale |
MR | Mixed reality |
OEND | Overdose education and naloxone distribution |
RCT | Randomized controlled trial |
SAMHSA | Substance Abuse and Mental Health Administration |
SPSS | Statistical Package for the Social Sciences |
ReviveXR | Mixed reality-based naloxone training |
VR | Virtual reality |
References
- Centers for Disease Control and Prevention (CDC). Drug Overdose Deaths in the United States, 2002–2022. Available online: https://www.cdc.gov/nchs/products/databriefs/db491.htm (accessed on 19 March 2025).
- Salmond, S.; Allread, V. A population health approach to America’s opioid epidemic. Orthop. Nurs. 2019, 38, 95–108. [Google Scholar] [CrossRef] [PubMed]
- Kennedy-Hendricks, A.; Ettman, C.K.; Gollust, S.E.; Bandara, S.N.; Abdalla, S.M.; Castrucci, B.C.; Galea, S. Experience of personal loss due to drug overdose among US adults. JAMA Health Forum 2024, 5, e241262. [Google Scholar] [CrossRef] [PubMed]
- National Center for Health Statistics. Drug Overdose Deaths in the United States, 1999–2020. Available online: https://www.cdc.gov/nchs/products/databriefs/db428.htm (accessed on 19 March 2025).
- Illinois Department of Public Health. Illinois Overdose Data Dashboard. Available online: https://dph.illinois.gov/topics-services/opioids/idph-data-dashboard/overdoses.html (accessed on 10 April 2025).
- National Center for Health Statistics. Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas—United States, 2015–2017. Available online: https://www.cdc.gov/mmwr/volumes/68/wr/mm6843a3.htm (accessed on 19 March 2025).
- Committee, J.E. The Economic Toll of the Opioid Crisis Reached Nearly $1.5 Trillion in 2020. Available online: https://www.jec.senate.gov/public/index.cfm/democrats/2022/9/the-economic-toll-of-the-opioid-crisis-reached-nearly-1-5-trillion-in-2020 (accessed on 19 March 2025).
- Veliz, P.T.; Schulenberg, J.E.; Zdroik, J.; Werner, K.S.; McCabe, S.E. The Initiation and Developmental Course of Prescription Drug Misuse Among High School Athletes During the Transition Through Young Adulthood. Am. J. Epidemiol. 2022, 191, 1886–1896. [Google Scholar] [CrossRef]
- Miech, R.; Johnston, L.; O’Malley, P.M.; Keyes, K.M.; Heard, K. Prescription opioids in adolescence and future opioid misuse. Pediatrics 2015, 136, e1169–e1177. [Google Scholar] [CrossRef]
- Groenewald, C.B. Opioid-prescribing Patterns for Pediatric Patients in the United States. Clin. J. Pain 2019, 35, 515–520. [Google Scholar] [CrossRef]
- Phillips, J.K.; Ford, M.A.; Bonnie, R.J. (Eds.) Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use; National Academies Press (US): Washington, DC, USA, 2017. [Google Scholar]
- National Center for Health Statistics. Drug Overdose Deaths with Evidence of Counterfeit Pill Use—United States, July 2019–December 2021. Morb. Mortal. Wkly. Rep. 2023, 72, 949–956. Available online: https://www.cdc.gov/mmwr/volumes/72/wr/mm7235a3.htm (accessed on 10 April 2025). [CrossRef]
- HIDTA. A Division for Advancing Prevention and Treatment. In Preventing Opioid Use and Overdose in School-Age Youth; HIDTA: New York, NY, USA, 2024. [Google Scholar]
- Bazazi, A.R.; Zaller, N.D.; Fu, J.J.; Rich, J.D. Preventing opiate overdose deaths: Examining objections to take-home naloxone. J. Health Care Poor Underserved 2010, 21, 1108–1113. [Google Scholar] [CrossRef]
- Lee, J.M.; Grabb, M.C.; Zipfel, G.J.; Choi, D.W. Brain tissue responses to ischemia. J. Clin. Investig. 2000, 106, 723–731. [Google Scholar] [CrossRef] [PubMed]
- Jayawardene, W.; Kumbalatara, C. Relationship between emergency response times and fatal opioid overdoses: A county-level analysis of Illinois data. In Proceedings of the Annual Conference of the American Public Health Association, Minneapolis, MN, USA, 30 October 2024. [Google Scholar]
- CDC. Drug Overdose Deaths Among Persons Aged 10–19 Years—United States, July 2019–December 2021. Available online: https://www.cdc.gov/mmwr/volumes/71/wr/mm7150a2.htm (accessed on 19 March 2025).
- Bessen, S.; Metcalf, S.A.; Saunders, E.C.; Moore, S.K.; Meier, A.; McLeman, B.; Walsh, O.; Marsch, L.A. Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA. Int. J. Drug. Policy 2019, 74, 144–151. [Google Scholar] [CrossRef]
- Irvine, M.A.; Oller, D.; Boggis, J.; Bishop, B.; Coombs, D.; Wheeler, E.; Doe-Simkins, M.; Walley, A.Y.; Marshall, B.D.L.; Bratberg, J.; et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: A modelling study. Lancet Public Health 2022, 7, e210–e218. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2018.
- Kuyt, K.; Park, S.-H.; Chang, T.P.; Jung, T.; MacKinnon, R. The use of virtual reality and augmented reality to enhance cardio-pulmonary resuscitation: A scoping review. Adv. Simul. 2021, 6, 11. [Google Scholar] [CrossRef]
- Ricci, S.; Calandrino, A.; Borgonovo, G.; Chirico, M.; Casadio, M. Viewpoint: Virtual and Augmented Reality in Basic and Advanced Life Support Training. JMIR Serious Games 2022, 10, e28595. [Google Scholar] [CrossRef]
- Herbert, N.; Axson, S.; Siegel, L.; Cassidy, K.; Hoyt-Brennan, A.M.; Whitney, C.; Herens, A.; Giordano, N.A. Leveraging immersive technology to expand access to opioid overdose reversal training in community settings: Results from a randomized controlled equivalence trial. Drug Alcohol Depend. 2020, 214, 108160. [Google Scholar] [CrossRef]
- Jayawardene, W.; Magnuson, R.; Kumbalatara, C.; Kase, M.; Goodson, A.; Park, A.; Willett, J.; Barrows, S.; Bolinski, R. Developing and testing the virtual reality embedded naloxone training (VENT) for layperson response to the opioid overdose crisis. In Proceedings of the Annual Conference of the American Public Health Association, Minneapolis, MN, USA, 29 October 2024. [Google Scholar]
- Venkatesan, M.; Mohan, H.; Ryan, J.R.; Schürch, C.M.; Nolan, G.P.; Frakes, D.H.; Coskun, A.F. Virtual and augmented reality for biomedical applications. Cell Rep. Med. 2021, 2, 100348. [Google Scholar] [CrossRef]
- Jayawardene, W. ReviveXR (Mixed Reality-Based Naloxone Training) Demo Video. 2025. Available online: https://youtu.be/ZugNL00iaI8 (accessed on 22 April 2025).
- Williams, A.V.; Strang, J.; Marsden, J. Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation. Drug Alcohol Depend. 2013, 132, 383–386. [Google Scholar] [CrossRef]
- Hecht, M.L.; Jayawardene, W.; Henderson, C.; Pezalla, A.; Flood-Grady, E.; Krieger, J.L.; Frederick, A.; Parker, M.; Ables, E. Developing the Opioid Rapid Response System™ for Lay Citizen Response to the Opioid Overdose Crisis: A Randomized Controlled Trial. Prev. Sci. 2023, 24, 1386–1397. [Google Scholar] [CrossRef]
- Kang, Y.N.; Chang, C.H.; Kao, C.C.; Chen, C.Y.; Wu, C.C. Development of a short and universal learning self-efficacy scale for clinical skills. PLoS ONE 2019, 14, e0209155. [Google Scholar] [CrossRef]
- IBM Corp. IBM SPSS Statistics for Windows; IBM Corp.: Armonk, NY, USA, 2022; 29.0. [Google Scholar]
- Freeman, P.R.; Walley, A.Y.; Winhusen, T.J.; Oga, E.A.; Villani, J.; Hunt, T.; Chandler, R.K.; Oyler, D.R.; Reilly, B.; Gelberg, K.; et al. Effect of the Communities That HEAL Intervention on Overdose Education and Naloxone Distribution: A Cluster-Randomized, Wait-List Controlled Trial. Am. J. Public Health 2025, 115, 83–94. [Google Scholar] [CrossRef]
- Horace, A.E.; Atawodi-Alhassan, O. Assessment of knowledge and behaviors of an opioid overdose education and naloxone distribution program during the coronavirus disease 2019 pandemic. Harm. Reduct. J. 2025, 22, 12. [Google Scholar] [CrossRef]
- Jayawardene, W.; Pezalla, A.; Henderson, C.; Hecht, M. Development of opioid rapid response system: Protocol for a randomized controlled trial. Contemp. Clin. Trials 2022, 115, 106727. [Google Scholar] [CrossRef]
- Gage, C.B.; Powell, J.R.; Ulintz, A.; Cash, R.E.; Lyons, M.S.; Wang, H.; Panchal, A.R. Layperson-Administered Naloxone Trends Reported in Emergency Medical Service Activations, 2020–2022. JAMA Netw. Open 2024, 7, e2439427. [Google Scholar] [CrossRef]
- Byles, H.; Sedaghat, N.; Rider, N.; Rioux, W.; Loverock, A.; Seo, B.; Dhanoa, A.; Orr, T.; Dunnewold, N.; Tjosvold, L.; et al. Barriers to calling emergency services amongst people who use substances in the event of overdose: A scoping review. Int. J. Drug Policy 2024, 132, 104559. [Google Scholar] [CrossRef]
- Kesich, Z.; Ibragimov, U.; Komro, K.; Lane, K.; Livingston, M.; Young, A.; Cooper, H.L.F. “I’m not going to lay back and watch somebody die”: A qualitative study of how people who use drugs’ naloxone experiences are shaped by rural risk environment and overdose education/naloxone distribution intervention. Harm Reduct. J. 2023, 20, 166. [Google Scholar] [CrossRef]
- Abdelal, R.; Raja Banerjee, A.; Carlberg-Racich, S.; Darwaza, N.; Ito, D.; Shoaff, J.; Epstein, J. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Harm Reduct. J. 2022, 19, 49. [Google Scholar] [CrossRef]
- Leece, P.N.; Hopkins, S.; Marshall, C.; Orkin, A.; Gassanov, M.A.; Shahin, R.M. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Can. J. Public Health 2013, 104, e200–e204. [Google Scholar] [CrossRef]
- Petrovitch, D.; Himes, K.P.; Jump, A.; Freiermuth, C.E.; Braun, R.S.; Brown, J.L.; Lyons, M.S.; Punches, B.E.; Sprague, J.E.; Littlefield, A.K. State program enables the identification of factors associated with naloxone awareness, self-efficacy, and use for overdose reversal: A cross-sectional, observational study in an urban emergency department population. J. Subst. Use Addict. Treat. 2024, 167, 209506. [Google Scholar] [CrossRef]
- Tormohlen, K.N.; Tobin, K.E.; Davey-Rothwell, M.A.; Latkin, C. Low overdose responding self-efficacy among adults who report lifetime opioid use. Drug Alcohol Depend. 2019, 201, 142–146. [Google Scholar] [CrossRef]
- Wagner, K.D.; Bovet, L.J.; Haynes, B.; Joshua, A.; Davidson, P.J. Training law enforcement to respond to opioid overdose with naloxone: Impact on knowledge, attitudes, and interactions with community members. Drug Alcohol Depend. 2016, 165, 22–28. [Google Scholar] [CrossRef]
- Van, S.P.; Yao, A.L.; Tang, T.; Kott, M.; Noles, A.; Dabai, N.; Coslick, A.; Rojhani, S.; Sprankle, L.A.; Hoyer, E.H. Implementing an Opioid Risk Reduction Program in the Acute Comprehensive Inpatient Rehabilitation Setting. Arch. Phys. Med. Rehabil. 2019, 100, 1391–1399. [Google Scholar] [CrossRef]
- Petterson, A.G.; Madah-Amiri, D. Overdose prevention training with naloxone distribution in a prison in Oslo, Norway: A preliminary study. Harm Reduct. J. 2017, 14, 74. [Google Scholar] [CrossRef]
- Feuerstein-Simon, R.; Lowenstein, M.; Dupuis, R.; Dolan, A.; Marti, X.L.; Harvey, A.; Ali, H.; Meisel, Z.F.; Grande, D.T.; Lenstra, N.; et al. Substance Use and Overdose in Public Libraries: Results from a Five-State Survey in the US. J. Community Health 2022, 47, 344–350. [Google Scholar] [CrossRef]
- Carter, G.; Caudill, P. Integrating naloxone education into an undergraduate nursing course: Developing partnerships with a local department of health. Public Health Nurs. 2020, 37, 439–445. [Google Scholar] [CrossRef]
- Argenyi, M.S.; Evans, J.K.; Gay, Y.; Epstein, D.H.; Weiss, S.T. The Opioid Overdose Resuscitation Education for Addiction Counselors and Trainees (Opioid Overdose REACT) naloxone response education pilot project improved confidence and knowledge among addiction counselors and trainees. Clin. Toxicol. 2023, 61, 509–517. [Google Scholar] [CrossRef]
- Wiederhold, B.K.; Riva, G.; Wiederhold, M.D. Virtual Reality in Healthcare: Medical Simulation and Experiential Interface. Stud. Health Technol. Inform. 2015, 219, 239. [Google Scholar]
- Nas, J.; Thannhauser, J.; Konijnenberg, L.S.F.; van Geuns, R.M.; van Royen, N.; Bonnes, J.L.; Brouwer, M.A. Long-term Effect of Face-to-Face vs Virtual Reality Cardiopulmonary Resuscitation (CPR) Training on Willingness to Perform CPR, Retention of Knowledge, and Dissemination of CPR Awareness: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open 2022, 5, e2212964. [Google Scholar] [CrossRef]
Survey Variable | Baseline Mean or Proportion (SD/SE) | Round 1 Mean or Proportion (SD/SE) | z or t Score | p Value |
---|---|---|---|---|
Overdose-Related Knowledge | ||||
Slow/shallow breathing (Correct = Yes) a | 0.80 (0.09) | 1.00 (0.00) | 2.24 | 0.025 |
Fits or convulsions (Correct = No) a | 0.24 (0.17) | 0.08 (0.19) | −2.00 | 0.046 |
Rapid heartbeat (Correct = No) a | 0.20 (0.18) | 0.12 (0.19) | −1.00 | 0.317 |
Loss of consciousness (Correct = Yes) a | 0.96 (0.04) | 1.00 (0.00) | 1.00 | 0.317 |
Very small pupils (Correct = Yes) a | 0.52 (0.14) | 0.88 (0.07) | 3.00 | 0.003 |
None of the above (Correct = No) a | 0.00 (0.00) | 0.00 (0.00) | - | - |
How long does naloxone take to start having effect? (2–5 min) b | 0.76 (0.10) | 0.96 (0.04) | 1.89 | 0.059 |
How long do the effects of naloxone last for? (1 h) b | 0.32 (0.16) | 0.72 (0.11) | 3.16 | 0.002 |
If the 1st dose of naloxone has no effect, a 2nd can be given. (True) a | 0.72 (0.11) | 1.00 (0.00) | 2.65 | 0.008 |
No need to call for an ambulance if I can manage overdose. (False) a | 0.04 (0.20) | 0.04 (0.20) | - | - |
Rescue breathing is effective when managing an opioid overdose: (1–5) c | 3.84 (1.03) | 4.68 (0.63) | 4.68 | 0.000 |
Chest compressions are effective when managing an opioid overdose: (1–5) c | 3.44 (1.04) | 3.72 (1.49) | 0.98 | 0.337 |
Naloxone is effective when managing an opioid overdose: (1–5) c | 4.84 (0.47) | 5.00 (0.00) | 1.69 | 0.103 |
I have enough information to respond to an overdose effectively. (1–5) c | 3.36 (1.55) | 4.76 (0.44) | 4.85 | 0.000 |
Confidence in Managing an Overdose | ||||
How confident are you in performing rescue breathing? (1–5) c | 3.60 (1.55) | 4.60 (0.58) | 4.08 | 0.000 |
How confident are you in performing chest compressions? (1–5) c | 3.44 (1.71) | 4.04 (1.46) | 1.81 | 0.083 |
How confident are you in performing naloxone administration? (1–5) c | 3.60 (1.47) | 4.88 (0.33) | 4.57 | 0.000 |
How comfortable do you feel responding to an overdose? (1–5) c | 3.44 (1.45) | 4.44 (0.82) | 3.87 | 0.001 |
Uncertainty in Managing an Overdose | ||||
I would be afraid of doing something wrong in an overdose situation (1–5) c | 2.68 (1.60) | 1.96 (1.34) | −2.42 | 0.023 |
I would need more naloxone training (1–5) c | 2.80 (1.66) | 1.88 (1.13) | −3.87 | 0.001 |
I would need more rescue breathing training (1–5) c | 2.64 (1.68) | 2.08 (1.50) | −2.02 | 0.055 |
Intent to Intervene in an Overdose Situation | ||||
Intent to utilize naloxone nasal spray (1–5) c | 4.16 (1.25) | 4.84 (0.47) | 3.07 | 0.005 |
Intent to utilize rescue breathing (1–5) c | 4.12 (0.97) | 4.64 (0.81) | 2.98 | 0.006 |
Intent to respond to an overdose event when notified (1–5) c | 4.28 (1.17) | 4.88 (0.33) | 2.78 | 0.010 |
Intent to utilize chest compressions (1–5) c | 3.88 (1.20) | 4.32 (1.25) | 1.90 | 0.069 |
Survey Variable | Round 1 Mean or Proportion (SD/SE) | Round 2 Mean or Proportion (SD/SE) | z or t Score | p Value |
---|---|---|---|---|
Overdose-Related Knowledge | ||||
Slow/shallow breathing (Correct = Yes) a | 1.00 (0.00) | 1.00 (0.00) | - | - |
Fits or convulsions (Correct = No) a | 0.10 (0.21) | 0.10 (0.21) | 0.00 | 1.000 |
Rapid heartbeat (Correct = No) a | 0.15 (0.21) | 0.05 (0.22) | −1.00 | 0.317 |
Loss of consciousness (Correct = Yes) a | 1.00 (0.00) | 1.00 (0.00) | - | - |
Very small pupils (Correct = Yes) a | 0.85 (0.09) | 0.80 (0.10) | −0.45 | 0.655 |
None of the above (Correct = No) a | 0.00 (0.00) | 0.00 (0.00) | - | - |
How long does naloxone take to start having effect? (2–5 min) b | 0.96 (0.04) | 0.80 (0.09) | −2.00 | 0.046 |
How long do the effects of naloxone last for? (1 h) b | 0.72 (0.11) | 0.40 (0.15) | −2.31 | 0.021 |
If the 1st dose of naloxone has no effect a 2nd can be given. (True) a | 1.00 (0.00) | 1.00 (0.00) | - | - |
No need to call for an ambulance if I can manage overdose. (False) a | 0.05 (0.22) | 0.00 (0.00) | −1.00 | 0.317 |
Rescue breathing is effective when managing an opioid overdose: (1–5) c | 4.80 (0.52) | 4.80 (0.41) | 0.00 | 1.000 |
Chest compressions are effective when managing an opioid overdose: (1–5) c | 3.60 (1.60) | 3.05 (1.61) | −1.93 | 0.069 |
Naloxone is effective when managing an opioid overdose: (1–5) c | 5.00 (0.00) | 5.00 (0.00) | - | - |
I have enough information to respond to an overdose effectively. (1–5) c | 4.75 (0.44) | 4.75 (0.44) | 0.00 | 1.000 |
Confidence in Managing an Overdose | ||||
How confident are you in performing rescue breathing? (1–5) c | 4.60 (0.60) | 4.45 (0.83) | −1.14 | 0.267 |
How confident are you in performing chest compressions? (1–5) c | 3.90 (1.59) | 3.70 (1.49) | −0.94 | 0.359 |
How confident are you in performing naloxone administration? (1–5) c | 4.90 (0.31) | 4.85 (0.49) | −0.57 | 0.577 |
How comfortable do you feel responding to an overdose? (1–5) c | 4.45 (0.83) | 4.25 (1.25) | −0.70 | 0.494 |
Uncertainty in Managing an Overdose | ||||
I would be afraid of doing something wrong in an overdose situation (1–5) c | 2.00 (1.38) | 1.70 (0.98) | −1.00 | 0.330 |
I would need more naloxone training (1–5) c | 1.85 (1.14) | 1.90 (1.21) | 0.19 | 0.853 |
I would need more rescue breathing training (1–5) c | 2.20 (1.54) | 1.70 (1.08) | −1.39 | 0.180 |
Intent to Intervene in an Overdose Situation | ||||
Intent to utilize naloxone nasal spray (1–5) c | 4.80 (0.52) | 4.65 (0.67) | −1.83 | 0.083 |
Intent to utilize rescue breathing (1–5) c | 4.60 (0.88) | 4.25 (1.16) | −2.10 | 0.049 |
Intent to respond to an overdose event when notified (1–5) c | 4.85 (0.37) | 4.55 (0.89) | −2.04 | 0.055 |
Intent to utilize chest compressions (1–5) c | 4.15 (1.35) | 4.10 (1.33) | −0.29 | 0.772 |
Survey Variable | Round 1 Mean (SD) | t Score | p Value |
---|---|---|---|
Cognitive | |||
I can recall how to perform naloxone administration. (1–5) a | 4.68 (0.85) | 9.85 | 0.000 |
I understand the content of naloxone administration and can demonstrate it to others. (1–5) a | 4.64 (0.57) | 14.42 | 0.000 |
I can verbally explain the purpose and principle of operating naloxone administration. (1–5) a | 4.76 (0.44) | 20.19 | 0.000 |
I can verbally explain the sequence and interrelationship between each step. (1–5) a | 4.64 (0.64) | 12.86 | 0.000 |
Affective | |||
I think it would be more beneficial if there was more of a focus on the naloxone training than the background information. (1–5) a | 3.00 (1.19) | 0.00 | 1.000 |
I think I gain more in learning about naloxone administration than in other content. (1–5) a | 3.88 (1.13) | 3.89 | 0.001 |
I tend to pay more attention to information related to naloxone administration content. (1–5) a | 3.88 (1.17) | 3.77 | 0.001 |
I tend to actively look for information related to naloxone administration. (1–5) a | 3.84 (1.21) | 3.46 | 0.002 |
Psychomotor | |||
I can precisely imitate the instructor’s steps and actions of naloxone administration. (1–5) a | 4.28 (0.89) | 7.19 | 0.000 |
I can smoothly complete the operation steps of naloxone administration. (1–5) a | 4.56 (0.58) | 13.38 | 0.000 |
I try to monitor my naloxone administration for improvements. (1–5) a | 4.52 (0.71) | 10.64 | 0.000 |
I try to monitor my naloxone administration operations and make proper adjustments as needed. (1–5) a | 4.48 (0.77) | 9.61 | 0.000 |
Survey Variable | Round 2 Mean (SD) | t Score | p Value |
---|---|---|---|
Cognitive | |||
I can recall how to perform naloxone administration. (1–5) a | 4.80 (0.41) | 19.62 | 0.000 |
I understand the content of naloxone administration and can demonstrate it to others. (1–5) a | 4.70 (0.57) | 13.31 | 0.000 |
I can verbally explain the purpose and principle of operating naloxone administration. (1–5) a | 4.70 (0.47) | 16.17 | 0.000 |
I can verbally explain the sequence and interrelationship between each step. (1–5) a | 4.65 (0.59) | 12.57 | 0.000 |
Affective | |||
I think it would be more beneficial if there was more of a focus on the naloxone training than the background information. (1–5) a | 3.00 (1.08) | 0.000 | 1.000 |
I think I gain more in learning about naloxone administration than in other content. (1–5) a | 3.35 (1.18) | 1.324 | 0.201 |
I tend to pay more attention to information related to naloxone administration content. (1–5) a | 3.55 (1.10) | 2.238 | 0.037 |
I tend to actively look for information related to naloxone administration. (1–5) a | 3.40 (1.10) | 1.633 | 0.119 |
Psychomotor | |||
I can precisely imitate the instructor’s steps and actions of naloxone administration. (1–5) a | 4.50 (0.69) | 9.75 | 0.000 |
I can smoothly complete the operation steps of naloxone administration. (1–5) a | 4.65 (0.49) | 15.08 | 0.000 |
I try to monitor my naloxone administration for improvements. (1–5) a | 4.00 (0.97) | 4.60 | 0.000 |
I try to monitor my naloxone administration operations and make proper adjustments as needed. (1–5) a | 4.30 (0.86) | 6.73 | 0.000 |
Parameter | Round 1 Training | Round 2 Training |
---|---|---|
Fit/Comfort | Some reported physical discomfort during use, including headset heaviness, mild headaches after extended use, eye strain, and difficulty fitting the headset with glasses. Positive feedback included comfort and ease of use, with comments like “didn’t notice I had headset on,” “manageable and comfortable,” and “easy to adjust.” Suggestions included a better nose-piece and a more comfortable headband. | Most participants found the headset adjustable and its weight manageable for shorter ReviveXR sessions (~15 min). However, some reported issues with eye strain, headset weight/sliding, and compatibility with glasses. |
Immersion | Participants had mixed feedback regarding the realism of the simulation. Some felt aware of the simulation, describing it as “looking like a videogame,” while others found it realistic, with one expressing surprise when the patient responded to their actions. Concerns about realism included unnatural patient behavior and unrealistic procedures. A suggestion was adding ambient sounds (e.g., store noise). | Participants mentioned the patient looking realistic, though some commented that not having a tactile response with the patient contributed to lower immersion level Participants noted that the haptic responses provided by the headset (triggered by performing actions correctly) enhanced immersion experience |
Engagement | Participants generally had positive feedback, expressing engagement and noting the clarity and simplicity of ReviveXR, with comments such as “easy” and “straightforward.” However, there was an instructional timing issue, with one participant mentioning that it was challenging when the instructor spoke while they were still processing actions, describing it as “incongruent.” | Most participants found the content and VR experience engaging, interesting, and appropriately concise, with feedback such as “not redundant, easy to follow.” The ability to move around and have hands-on experience was highlighted as a key factor in maintaining engagement throughout the training. |
Affect | No serious emotional responses reported. Felt “fine” was a common response. | Participants overall felt “good” and “unstressed”. |
Interactivity | Challenges were awkward interactions with virtual objects, uncertainty about action recognition, and difficulty adjusting to the pinch motion. Navigation was easy, and the pass-through component was praised. | Participants stated that moving through and interacting with ReviveXR was intuitive. |
Comparison with the traditional training | The use of patient response simulations was praised for enhancing realism and improving efficiency compared with traditional CPR training with plastic busts. The approach was seen as an effective method for building knowledge and confidence in assisting with opioid overdoses. However, some noted that the focus on technology occasionally detracted from the core training content. | The incorporation of VR-based approaches received a positive reception. Participants highlighted the realism of the experience, with one noting that it closely resembles real-world scenarios and aids in developing muscle memory. However, the absence of tactile feedback, which is typically provided by physical mannequins, was noted as a limitation. One pointed out that while ReviveXR is effective for general use, it may not be as well-suited for techniques requiring precise hands-on skills, such as CPR. |
Content improvements needed | The rescue breathing portion was seen as overly emphasized, with some participants feeling it received disproportionate focus. Also, the activity requiring participants to identify objects, including paraphernalia, was considered unnecessary by some. | A participant felt that it needs to be noted that rescue breaths require a barrier/mask. Overall, participants considered content to be comprehensive and succinct. |
Technical improvements needed | Participants noted occasional glitches with object placement and instructional text visibility. Incorporating introductory video into main training platform was suggested. | Improved graphics and removal of object scanning were considered by participants as significant improvements and generally noted a smoother experience. Participants reported initial confusion with the Panel Movement button and difficulty seeing the chest rise and fall despite clear instructions. Additionally, the phone interaction was unclear, with one participant mentioning uncertainty about when to pull the phone out of their pocket during the training. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jayawardene, W.; Magnuson, R.; Kumbalatara, C.; Kase, M.; Park, A.; Goodson, A.; Barrows, S.; Bolinski, R.; Willett, J. Usability of Mixed Reality for Naloxone Training: Iterative Development and Field Testing of ReviveXR. Healthcare 2025, 13, 1449. https://doi.org/10.3390/healthcare13121449
Jayawardene W, Magnuson R, Kumbalatara C, Kase M, Park A, Goodson A, Barrows S, Bolinski R, Willett J. Usability of Mixed Reality for Naloxone Training: Iterative Development and Field Testing of ReviveXR. Healthcare. 2025; 13(12):1449. https://doi.org/10.3390/healthcare13121449
Chicago/Turabian StyleJayawardene, Wasantha, Roy Magnuson, Chesmi Kumbalatara, Matthew Kase, Amy Park, Alana Goodson, Scott Barrows, Rebecca Bolinski, and Joanna Willett. 2025. "Usability of Mixed Reality for Naloxone Training: Iterative Development and Field Testing of ReviveXR" Healthcare 13, no. 12: 1449. https://doi.org/10.3390/healthcare13121449
APA StyleJayawardene, W., Magnuson, R., Kumbalatara, C., Kase, M., Park, A., Goodson, A., Barrows, S., Bolinski, R., & Willett, J. (2025). Usability of Mixed Reality for Naloxone Training: Iterative Development and Field Testing of ReviveXR. Healthcare, 13(12), 1449. https://doi.org/10.3390/healthcare13121449